Trial
NCT01108458
A Phase 2 Study of Pertuzumab and Erlotinib for Refractory Pancreatic Adenocarcinoma
Phase IITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
George Albert Fisher
Collaborators
Genentech, Inc.
Condition
Pancreatic Cancer
Intervention
Pertuzumab
Why stopped
Extreme toxicity of Pertuzumab and Erlotinib combination
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-03-03